Latest Optimer Pharmaceuticals (OPTR) Headlines
Post# of 1
Posted On: 03/13/2014 12:05:39 PM
Latest Optimer Pharmaceuticals (OPTR) Headlines
Optronics Releases New 2014 Vehicle Lighting Catalog
PRWeb - Mon Mar 10, 3:09AM CDT
Optronics International, America's largest offshore vehicle lighting manufacturer, announced the release of its new 2014 Lighting Product Catalog today. The 276-page document features 523 new products among the 3,095 total SKUs cataloged. In addition to the physical catalog, Optronics has made the content available in the form of a downloadable PDF, and all product data is also searchable on the company's website.
Optronics Introduces "Combo Lamp" with Integrated Stop, Tail, Turn and Backup Functions at 2014 Work Truck Show
PRWeb - Mon Mar 03, 2:55AM CST
Optronics International, America's largest offshore vehicle lighting manufacturer, announced that it will reveal its new STL68 Combo Lamp for the first time in booth 5747 at the 2014 NTEA Work Truck Show in Indianapolis, Ind. The nine-inch oval combination LED stop, tail, turn and backup lamp easily mounts to the surface of a vehicle and at only half an inch thick, has the low profile of a through-hole-mounted lamp.
Razor® to Debut New Scooters and Ride-Ons at the American International Toy Fair
PR Newswire - Fri Feb 14, 7:00AM CST
Razor USA LLC, innovators of outdoor fun and home of the iconic Razor kick scooter, will unveil their 2014 product line at the American International Toy Fair, February 16-19, 2014 in New York City. The new line features unique Razor Jr. scooters and ride-ons for young riders, as well as an electric-powered trike for older kid thrill-seekers. Razor's mission is to reinvent classic rides with innovation and break-out appeal, and inspire riders and families everywhere to get outside, ride and play.
Leading M&A Lawyer Mikhail Semyonov Joins Baker Botts in Moscow
PR Newswire - Tue Jan 07, 10:00AM CST
Leading mergers & acquisitions lawyer Mikhail Semyonov has joined Baker Botts as a Global Projects partner in its Moscow office.
Research Report: Cystic Fibrosis - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wfwrck/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cystic Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Genzyme Corporation Johnson & Johnson Boehringer Ingelheim GmbH GlaxoSmithKline plc Gilead Sciences, Inc. Vectura Group plc Novartis AG Axcan Pharma Inc. Chiesi Farmaceutici SpA Pfizer Inc. Vertex Pharmaceuticals Incorporated Zambon Group S.p.A. Optimer Pharmaceuticals, Inc. PARI Pharma GmbH Hollis-Eden Pharmaceuticals, Inc. Pharmaxis Ltd. CSL Limited Protalix BioTherapeutics, Inc. Lipoxen PLC Galapagos NV Kamada Ltd. Proteo, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/wf...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cubist Pharmaceuticals Inc acquires USD551m Optimer Pharmaceuticals
M2 - Fri Oct 25, 3:01AM CDT
Biopharmaceutical company Cubist Pharmaceuticals Inc (NasdaqGS:CBST) announced on Thursday the completion of the acquisition of Optimer Pharmaceuticals Inc (OPTR) for an aggregate upfront cash consideration of approximately USD551m.
Cubist Pharmaceuticals Completes Acquisition of Optimer Pharmaceuticals
Business Wire - Thu Oct 24, 8:45AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today that it has completed its acquisition of Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) for an aggregate upfront cash consideration of approximately $551 million. Optimer stockholders approved the merger agreement at a special meeting of stockholders held on October 23, 2013. Effective today, Optimer common stock will cease to be traded on the NASDAQ.
Cubist Pharma Misses on Earnings and Revenues in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 23, 9:30AM CDT
Cubist reported lower than expected earnings in the third quarter.
Hart-Scott-Rodino Waiting Period Expires for Cubist Acquisition of Optimer
Business Wire - Fri Sep 13, 7:30AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") in connection with the previously announced merger agreement under which Cubist will acquire all of the outstanding common stock of Optimer.
Cubist Pharma Prices Senior Notes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 10, 4:00PM CDT
Cubist Pharma priced convertible senior notes.
Voluntary Recall at Cubist Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 30, 10:00AM CDT
Cubist Pharma voluntarily recalled four lots of Cubicin.
Today's Research: Inovio Pharmaceuticals Inc., Onyx Pharmaceuticals Inc., Sequenom Inc. and Optimer Pharmaceuticals Inc.
PR Newswire - Thu Aug 29, 8:01AM CDT
The U.S. equity market ended higher on Wednesday, August 28, 2013. The S&P 500 advanced 0.27%, to close the day at 1,634.96. Shares of companies in the biotechnology industry also ended on a higher note, tracking gains in the broader market. The major movers included Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), Sequenom Inc. (NASDAQ: SQNM), and Optimer Pharmaceuticals Inc. (NASDAQ: OPTR). AAAResearchReports.com has completed their technical analysis on INO, ONXX, SQNM, and OPTR and these free reports are accessible by registering at:
Still Neutral on Cubist Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 20, 3:00PM CDT
We still have a Neutral recommendation on Cubist Pharma.
Optronics Releases New 2014 Vehicle Lighting Catalog
PRWeb - Mon Mar 10, 3:09AM CDT
Optronics International, America's largest offshore vehicle lighting manufacturer, announced the release of its new 2014 Lighting Product Catalog today. The 276-page document features 523 new products among the 3,095 total SKUs cataloged. In addition to the physical catalog, Optronics has made the content available in the form of a downloadable PDF, and all product data is also searchable on the company's website.
Optronics Introduces "Combo Lamp" with Integrated Stop, Tail, Turn and Backup Functions at 2014 Work Truck Show
PRWeb - Mon Mar 03, 2:55AM CST
Optronics International, America's largest offshore vehicle lighting manufacturer, announced that it will reveal its new STL68 Combo Lamp for the first time in booth 5747 at the 2014 NTEA Work Truck Show in Indianapolis, Ind. The nine-inch oval combination LED stop, tail, turn and backup lamp easily mounts to the surface of a vehicle and at only half an inch thick, has the low profile of a through-hole-mounted lamp.
Razor® to Debut New Scooters and Ride-Ons at the American International Toy Fair
PR Newswire - Fri Feb 14, 7:00AM CST
Razor USA LLC, innovators of outdoor fun and home of the iconic Razor kick scooter, will unveil their 2014 product line at the American International Toy Fair, February 16-19, 2014 in New York City. The new line features unique Razor Jr. scooters and ride-ons for young riders, as well as an electric-powered trike for older kid thrill-seekers. Razor's mission is to reinvent classic rides with innovation and break-out appeal, and inspire riders and families everywhere to get outside, ride and play.
Leading M&A Lawyer Mikhail Semyonov Joins Baker Botts in Moscow
PR Newswire - Tue Jan 07, 10:00AM CST
Leading mergers & acquisitions lawyer Mikhail Semyonov has joined Baker Botts as a Global Projects partner in its Moscow office.
Research Report: Cystic Fibrosis - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wfwrck/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cystic Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Genzyme Corporation Johnson & Johnson Boehringer Ingelheim GmbH GlaxoSmithKline plc Gilead Sciences, Inc. Vectura Group plc Novartis AG Axcan Pharma Inc. Chiesi Farmaceutici SpA Pfizer Inc. Vertex Pharmaceuticals Incorporated Zambon Group S.p.A. Optimer Pharmaceuticals, Inc. PARI Pharma GmbH Hollis-Eden Pharmaceuticals, Inc. Pharmaxis Ltd. CSL Limited Protalix BioTherapeutics, Inc. Lipoxen PLC Galapagos NV Kamada Ltd. Proteo, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/wf...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cubist Pharmaceuticals Inc acquires USD551m Optimer Pharmaceuticals
M2 - Fri Oct 25, 3:01AM CDT
Biopharmaceutical company Cubist Pharmaceuticals Inc (NasdaqGS:CBST) announced on Thursday the completion of the acquisition of Optimer Pharmaceuticals Inc (OPTR) for an aggregate upfront cash consideration of approximately USD551m.
Cubist Pharmaceuticals Completes Acquisition of Optimer Pharmaceuticals
Business Wire - Thu Oct 24, 8:45AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today that it has completed its acquisition of Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) for an aggregate upfront cash consideration of approximately $551 million. Optimer stockholders approved the merger agreement at a special meeting of stockholders held on October 23, 2013. Effective today, Optimer common stock will cease to be traded on the NASDAQ.
Cubist Pharma Misses on Earnings and Revenues in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 23, 9:30AM CDT
Cubist reported lower than expected earnings in the third quarter.
Hart-Scott-Rodino Waiting Period Expires for Cubist Acquisition of Optimer
Business Wire - Fri Sep 13, 7:30AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") in connection with the previously announced merger agreement under which Cubist will acquire all of the outstanding common stock of Optimer.
Cubist Pharma Prices Senior Notes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 10, 4:00PM CDT
Cubist Pharma priced convertible senior notes.
Voluntary Recall at Cubist Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 30, 10:00AM CDT
Cubist Pharma voluntarily recalled four lots of Cubicin.
Today's Research: Inovio Pharmaceuticals Inc., Onyx Pharmaceuticals Inc., Sequenom Inc. and Optimer Pharmaceuticals Inc.
PR Newswire - Thu Aug 29, 8:01AM CDT
The U.S. equity market ended higher on Wednesday, August 28, 2013. The S&P 500 advanced 0.27%, to close the day at 1,634.96. Shares of companies in the biotechnology industry also ended on a higher note, tracking gains in the broader market. The major movers included Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), Sequenom Inc. (NASDAQ: SQNM), and Optimer Pharmaceuticals Inc. (NASDAQ: OPTR). AAAResearchReports.com has completed their technical analysis on INO, ONXX, SQNM, and OPTR and these free reports are accessible by registering at:
Still Neutral on Cubist Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 20, 3:00PM CDT
We still have a Neutral recommendation on Cubist Pharma.
(0)
(0)Optimer Pharmaceuticals (OPTR) Stock Research Links
Scroll down for more posts ▼